Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP reduced its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 18.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 147,932 shares of the company’s stock after selling 34,130 shares during the quarter. GSA Capital Partners LLP’s holdings in Tenaya Therapeutics were worth $286,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. RA Capital Management L.P. grew its holdings in Tenaya Therapeutics by 4.5% during the first quarter. RA Capital Management L.P. now owns 5,755,050 shares of the company’s stock worth $30,099,000 after acquiring an additional 247,703 shares during the period. Vanguard Group Inc. boosted its position in Tenaya Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock worth $14,973,000 after purchasing an additional 403,472 shares in the last quarter. Integral Health Asset Management LLC boosted its position in Tenaya Therapeutics by 3.3% in the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock worth $7,208,000 after purchasing an additional 75,000 shares in the last quarter. abrdn plc purchased a new position in shares of Tenaya Therapeutics during the 3rd quarter valued at approximately $1,063,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Tenaya Therapeutics by 12.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 237,597 shares of the company’s stock valued at $737,000 after purchasing an additional 26,103 shares during the period. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TNYA shares. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reduced their target price on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $16.00 price target on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $14.75.

Tenaya Therapeutics Stock Performance

Shares of TNYA stock opened at $2.38 on Friday. The stock has a market capitalization of $188.54 million, a P/E ratio of -1.65 and a beta of 2.34. The company has a 50 day moving average price of $2.02 and a 200 day moving average price of $2.87. Tenaya Therapeutics, Inc. has a fifty-two week low of $1.61 and a fifty-two week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.07. On average, research analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.